FeesSafety
Pluang+

Metagenomi CEO to discuss next-gen genome editing at Chardan Healthcare Conference

Market News
13 Oct 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Metagenomi CEO to discuss next-gen genome editing at Chardan Healthcare Conference

Metagenomi Therapeutics announced that its CEO, Jian Irish, will participate in a panel on advanced genome editing technologies at the Chardan 10th Annual Healthcare Conference on October 20, 2026. The company focuses on developing curative genetic medicines using proprietary CRISPR-based tools, with a lead program MGX-001 targeting hemophilia A showing promising preclinical results. This event highlights Metagenomi's role in advancing genome editing beyond current CRISPR methods, potentially impacting future genetic therapies.

Metagenomi Therapeutics, Inc. is the subject of this update. For readers following the health sector, here is Pluang's market snapshot: out of 128 priced US health-sector stocks, 78 rose and 41 fell. Notable movers include LFST at USD 12.69 (+1.68%), NBIX at USD 139.05 (-1.64%) with 100% sell order activity, and SNY at USD 40.37 (+1.59%) with 74% buy order activity. Data is as of Oct 13, 2026 18:02 WIB.

More News

AMG TimesSquare Small Cap Growth Fund beats Russell 2000 Growth Index in Q3 2026 with strong sector performance.

AMG TimesSquare Small Cap Growth Fund beats Russell 2000 Growth Index in Q3 2026 with strong sector performance.

In Q3 2026, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index, driven by strong holdings in Information Technology, Financials, and Consumer Staples sectors. The fund's success was attributed to company-specific fundam...

Market News
Bullish
5 hours ago
Schwab US Dividend Equity ETF rallies 10% on strong earnings and dividend inflows, with 8% upside potential.

Schwab US Dividend Equity ETF rallies 10% on strong earnings and dividend inflows, with 8% upside potential.

The Schwab US Dividend Equity ETF (SCHD) has rallied about 10% since early October, supported by stronger earnings from key holdings like Texas Instruments and UnitedHealth, as well as inflows into dividend-focused funds. SCHD trades at roughly 18.6 ...

Market News
Bullish
5 hours ago
Helus Pharma to reveal Phase 3 trial results for depression drug HLP003 on Nov 16, 2026

Helus Pharma to reveal Phase 3 trial results for depression drug HLP003 on Nov 16, 2026

Helus Pharma will present topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disorder on November 16, 2026. This drug has received Breakthrough Therapy Designation from the FDA, highlight...

Market News
Neutral
5 hours ago
Eaton Vance ETG fund hikes monthly payout 23.7%, trading at 11%+ discount to NAV

Eaton Vance ETG fund hikes monthly payout 23.7%, trading at 11%+ discount to NAV

Eaton Vance Tax-Advantaged Global Dividend Income Fund (ETG) raised its monthly distribution by 23.7%, marking its highest payout since inception. Despite this increase and strong long-term returns, ETG shares trade at a significant discount of over ...

Market News
Bullish
5 hours ago
Treasury Secretary demands major changes at Nvidia amid CEO resignation and export control concerns.

Treasury Secretary demands major changes at Nvidia amid CEO resignation and export control concerns.

U.S. Treasury Secretary Scott Bessent called for a major overhaul at Nvidia following CEO Jensen Huang's resignation amid allegations of illicit chip sales to China. Bessent urged the company to hire an external CEO and suggested scrutiny of other ex...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App